The latest report on “Ulcerative Colitis Market (Drug Type – Anti-inflammatory Drugs, Anti-TNF Biologics, Immunosuppressant, Calcineurin Inhibitors, and Other Drug Types; Disease Type – Ulcerative Proctitis, Proctosigmoiditis, Left-sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025.”
For More Details Get FREE Sample Pages of this Research Report@ https://www.infiniumglobalresearch.com/reports/sample-request/14100
According to the CDC (Centers for Disease Control), the worldwide incidence of ulcerative colitis is between 0.5 to 24.5 cases per 100,000 persons per year. The recurrence of the disease’s symptoms is also high. Recently, numerous medical treatments for ulcerative colitis have developed. 5-aminosalicylic acids (5-ASAs), corticosteroids, thiopurine, calcineurin inhibitors, and anti-tumor necrosis factor (TNF) treatments are recent medical treatments. Furthermore, golimumab, vedolizumab, AJM300, tofacitinib are some upcoming treatments. Budesonide foam will be used as one treatment option in patients with distal colitis. Herbal medicine is also effective for active UC. In the near future, physicians will able to use many different treatments for UC patients.
The rising incidence of ulcerative colitis disease across the globe is the major driving factor for the ulcerative colitis market. Furthermore, factors such as advancements in the healthcare industry in the past few years, the arrival of enhanced drugs, and increasing research explorations to develop an innovative treatment for ulcerative colitis are other driving factors for the growth of the market. Increasing demand for better treatment procedures along with developing healthcare infrastructures is fueling the ulcerative colitis market growth. However, stringent government regulations towards the approval of biosimilars restrain market growth. Moreover, unmet needs in the treatment of ulcerative colitis are expected to provide lucrative growth opportunities for the ulcerative colitis market.
Geographically, North America dominates the global ulcerative colitis market owing to the presence of key players and the growing prevalence of the disease in the region. The continuing funding for the development of new therapeutics for the treatment of the condition also drives the market growth in North America. Asia-Pacific is the second-largest market for ulcerative colitis due to expanding incidences of ulcerative colitis accompanied by the expansion of the drug development sector in this region. Ulcerative colitis is increasing in several parts of Asia with gender distribution and age of diagnosis.
The report on the global ulcerative colitis market covers segments such as drug type and disease type. On the basis of drug type, the sub-markets include anti-inflammatory drugs, anti-TNF biologics, immunosuppressant, calcineurin inhibitors, and other drug types. On the basis of disease type, the sub-markets include ulcerative proctitis, proctosigmoiditis, left-sided colitis, pancolitis or universal colitis, and fulminant colitis.
Browse Detailed TOC and Description of this Exclusive Report@ https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-ulcerative-colitis-market
The report provides profiles of the companies in the market such as GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Sanofi Aventis A/S, AstraZeneca plc, Abbott Laboratories, Merck & Co., Inc., InDex Pharmaceuticals Holding AB, Ajinomoto Pharmaceuticals Co., Ltd., Avaxia Biologics Inc., and other companies.
Reasons to Buy this Report:
=> Comprehensive analysis of global as well as regional markets of the ulcerative colitis.
=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.
=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.